These recognized disparities have been reported and proposed as racial disparities in the disease biology impacting prognosis, genetic predisposition and characterization based on race and ethnic background of patients, and access-to-care which impacts disease stage at time of diagnosis as well as biomarker, imaging, and management offerings. Despite PSA screening, well-established disease management options, and ongoing advances in cancer risk-stratification with more novel imaging and biomarkers, there continues to be a wide range of cancer treatment outcomes largely attributed to disparities in underlying biology, access to screening, risk stratification tools used, and treatments employed. Prostate cancer (PCa) is the most common non-cutaneous malignancy in American men with the second highest rate of annual cancer-related mortality.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |